Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP3325 in Healthy Japanese and Caucasian Subjects
NCT02500953Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP3325 in hyperphosphatemia (3 arms), sponsored by Astellas Pharma. Primary endpoints: Safety developed by adverse events at Day 13, Safety developed by Vital signs at Day 13 and 2 more. Started Jul 2013; status: completed.
02
Drugs
ASP3325
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT02500953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500953.